A randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly people
To provide new information regarding the role of aliskiren based BP lowering (with additional therapy with diuretics or CCB) in elderly individuals with SBP 130 to 159 mm Hg, in preventing major CV events and on global measures of physical, executive and cognitive function
Randomized, multicenter, double 2X2 factorial design.
The composite of CV death, non-fatal MI, non-fatal stroke, and significant heart failure; Secondary endpoints: Decline in the ability to perform everyday activities (key secondary outcome), renal dysfunction, and total mortality
Koon Teo, Salim Yusuf
Teo KK, Pfeffer M, Mancia G, O’Donnell M, Dagenais G, Diaz R, Dans A, Liu L, Bosch J, Joseph P, Copland I, Jung H, Pogue J, Yusuf S, Aliskiren Prevention of Later Life Outcomes trial Investigators. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. Eur Heart J. 2014 Jul;35(26):1743-51. doi: 10.1093/eurheartj/ehu079. Epub 2014 Mar 9.